DEVELOPMENTAL FUNDS Developmental Funds support the Lineberger Comprehensive Cancer Center (LCCC) mission directly through the provision of resources and indirectly by leveraging institutional and philanthropic assets. Collectively, these resources expand and enhance cancer research across LCCC in the basic, clinical, population and translational sciences. During the last five years, these funds have been used to make key recruitments and to launch innovative ideas through pilot project funding. Through these expenditures, the LCCC bolstered interdisciplinary and translational research efforts. By objective criteria such as extramural grants funded and junior faculty garnering national awards, LCCC recruitment efforts have been a stunning success. The competition for pilot project awards occurs twice yearly both with a general call for innovative ideas and specific RFAs devised by the Senior and Program Leaders to stimulate ideas arising from the LCCC planning processes. The awards have initiated new research across the clinical, population, translational, and basic spectrums, again yielding success in seeding extramural grant funding, broad collaborations, and cancer related publications. As has been the case over the last decade, Developmental Funds have been a key to growth, innovation, and the Center?s scientific and clinical impact. The Center distributed over $14.0M over the 5 year period and received a return on investment of $77M. LCCC requests $650,000 in this category, per year, in this renewal application, justified by past success and needs for a growing Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-45
Application #
10089821
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-06-01
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Byrne, James D; Yeh, Jen Jen; DeSimone, Joseph M (2018) Use of iontophoresis for the treatment of cancer. J Control Release 284:144-151
Wilkin, Timothy J; Chen, Huichao; Cespedes, Michelle S et al. (2018) A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis 67:1339-1346
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Ubil, Eric; Caskey, Laura; Holtzhausen, Alisha et al. (2018) Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response. J Clin Invest 128:2356-2369
Hamad, Ahmad; Iweala, Onyinye I; Henderson, Cory et al. (2018) Recurrent anaphylaxis during cardiac catheterization due to ethylene oxide. J Allergy Clin Immunol Pract 6:2148-2150
Mayer, Deborah K; Landucci, Gina; Awoyinka, Lola et al. (2018) SurvivorCHESS to increase physical activity in colon cancer survivors: can we get them moving? J Cancer Surviv 12:82-94
Huo, Dezheng; Perou, Charles M; Olopade, Olufunmilayo I (2018) Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening-Reply. JAMA Oncol 4:883-884
Howe, Chanelle J; Robinson, Whitney R (2018) Survival-related Selection Bias in Studies of Racial Health Disparities: The Importance of the Target Population and Study Design. Epidemiology 29:521-524
Brighton, Hailey E; Angus, Steven P; Bo, Tao et al. (2018) New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging. Cancer Res 78:542-557
Troester, Melissa A; Sun, Xuezheng; Allott, Emma H et al. (2018) Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst 110:

Showing the most recent 10 out of 1525 publications